|
1
|
Quint K, Stiel N, Neureiter D, Schlicker
HU, Nimsky C, Ocker M, Strik H and Kolodziej MA: The role of
sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and
S1P5 in primary, secondary, and recurrent glioblastomas. Tumour
Biol. 35:8979–8989. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Strub GM, Maceyka M, Hait NC, Milstien S
and Spiegel S: Extracellular and intracellular actions of
sphingosine-1-phosphate. Adv Exp Med Biol. 688:141–155. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Estrada-Bernal A, Palanichamy K, Ray
Chaudhury A and Van Brocklyn JR: Induction of brain tumor stem cell
apoptosis by FTY720: A potential therapeutic agent for
glioblastoma. Neuro Oncol. 14:405–415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ocker M, Tackenberg B and Strik H:
Fingolimod. Nervenheilkunde. 30:345–349. 2011. View Article : Google Scholar
|
|
5
|
Ponnusamy S, Meyers-Needham M, Senkal CE,
Saddoughi SA, Sentelle D, Selvam SP, Salas A and Ogretmen B:
Sphingolipids and cancer: Ceramide and sphingosine-1-phosphate in
the regulation of cell death and drug resistance. Future Oncol.
6:1603–1624. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bassi R, Anelli V, Giussani P, Tettamanti
G, Viani P and Riboni L: Sphingosine-1-phosphate is released by
cerebellar astrocytes in response to bFGF and induces astrocyte
proliferation through Gi-protein-coupled receptors. Glia.
53:621–630. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Spiegel S and Milstien S:
Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol
Cell Biol. 4:397–407. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Obinata H and Hla T: Sphingosine
1-phosphate in coagulation and inflammation. Semin Immunopathol.
34:73–91. 2012. View Article : Google Scholar
|
|
9
|
Mendelson K, Evans T and Hla T:
Sphingosine 1-phosphate signalling. Development. 141:5–9. 2014.
View Article : Google Scholar
|
|
10
|
Mora R, Dokic I, Kees T, Hüber CM, Keitel
D, Geibig R, Brügge B, Zentgraf H, Brady NR and Régnier-Vigouroux
A: Sphingolipid rheostat alterations related to transformation can
be exploited for specific induction of lysosomal cell death in
murine and human glioma. Glia. 58:1364–1383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Anelli V, Gault CR, Snider AJ and Obeid
LM: Role of sphin-gosine kinase-1 in paracrine/transcellular
angiogenesis and lymphangiogenesis in vitro. FASEB J. 24:2727–2738.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Riccitelli E, Giussani P, Di Vito C,
Condomitti G, Tringali C, Caroli M, Galli R, Viani P and Riboni L:
Extracellular sphingo-sine-1-phosphate: A novel actor in human
glioblastoma stem cell survival. PLoS One. 8:e682292013. View Article : Google Scholar
|
|
13
|
Mahajan-Thakur S, Bien-Möller S, Marx S,
Schroeder H and Rauch BH: Sphingosine 1-phosphate (S1P) signaling
in glioblastoma multiforme-A systematic review. Int J Mol Sci.
18:24482017. View Article : Google Scholar
|
|
14
|
Rosen H and Goetzl EJ: Sphingosine
1-phosphate and its receptors: An autocrine and paracrine network.
Nat Rev Immunol. 5:560–570. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Inda MM, Bonavia R and Seoane J:
Glioblastoma multiforme: A look inside its heterogeneous nature.
Cancers (Basel). 6:226–239. 2014. View Article : Google Scholar
|
|
16
|
Bektas M, Johnson SP, Poe WE, Bigner DD
and Friedman HS: A sphingosine kinase inhibitor induces cell death
in temozolomide resistant glioblastoma cells. Cancer Chemother
Pharmacol. 64:1053–1058. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xia X, Li X, Li F, Wu X, Zhang M, Zhou H,
Huang N, Yang X, Xiao F, Liu D, et al: A novel tumor suppressor
protein encoded by circular AKT3 RNA inhibits glioblastoma
tumorigenicity by competing with active phosphoinositide-dependent
Kinase-1. Mol Cancer. 18:1312019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chin YR, Yuan X, Balk SP and Toker A:
PTEN-deficient tumors depend on AKT2 for maintenance and survival.
Cancer Discov. 4:942–955. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen WS: Growth retardation and increased
apoptosis in mice with homozygous disruption of the akt1 gene.
Genes Dev. 15:2203–2208. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Degtyarev M, De Mazière A, Orr C, Lin J,
Lee BB, Tien JY, Prior WW, van Dijk S, Wu H, Gray DC, et al: Akt
inhibition promotes autophagy and sensitizes PTEN-null tumors to
lysosomotropic agents. J Cell Biol. 183:101–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang L, Wang H, Ding K and Xu J: FTY720
induces autophagy-related apoptosis and necroptosis in human
glioblastoma cells. Toxicol Lett. 236:43–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brinkmann V: Sphingosine 1-phosphate
receptors in health and disease: Mechanistic insights from gene
deletion studies and reverse pharmacology. Pharmacol Ther.
115:84–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vessey DA, Kelley M, Zhang J, Li L, Tao R
and Karliner JS: Dimethylsphingosine and FTY720 inhibit the SK1
form but activate the SK2 form of sphingosine kinase from rat
heart. J Biochem Mol Toxicol. 21:273–279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Patil SM, Beck PP, Arora N, Acevedo BA and
Dandachi D: Primary cutaneous cryptococcal infection due to
fingolimod- Induced lymphopenia with literature review. IDCases.
21:e008102020. View Article : Google Scholar
|
|
25
|
Mullins CS, Schneider B, Stockhammer F,
Krohn M, Classen CF and Linnebacher M: Establishment and
characterization of primary glioblastoma cell lines from fresh and
frozen material: A detailed comparison. PLoS One. 8:2013.
View Article : Google Scholar
|
|
26
|
Van Brocklyn JR, Jackson CA, Pearl DK,
Kotur MS, Snyder PJ and Prior TW: Sphingosine kinase-1 expression
correlates with poor survival of patients with glioblastoma
multiforme: Roles of sphingosine kinase isoforms in growth of
glioblastoma cell lines. J Neuropathol Exp Neurol. 64:695–705.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rosa R, Marciano R, Malapelle U, Formisano
L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio
S, et al: Sphingosine kinase 1 overexpression contributes to
cetuximab resistance in human colorectal cancer models. Clin Cancer
Res. 19:138–147. 2013. View Article : Google Scholar
|
|
28
|
Chiba K, Matsuyuki H, Maeda Y and Sugahara
K: Role of sphingosine 1-phosphate receptor type 1 in lymphocyte
egress from secondary lymphoid tissues and thymus. Cell Mol
Immunol. 3:11–19. 2006.PubMed/NCBI
|
|
29
|
Ishitsuka A, Fujine E, Mizutani Y, Tawada
C, Kanoh H, Banno Y and Seishima M: FTY720 and cisplatin
synergistically induce the death of cisplatin-resistant melanoma
cells through the downregulation of the PI3K pathway and the
decrease in epidermal growth factor receptor expression. Int J Mol
Med. 34:1169–1174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stafman LL, Williams AP, Marayati R, Aye
JM, Stewart JE, Mroczek-Musulman E and Beierle EA: PP2A activation
alone and in combination with cisplatin decreases cell growth and
tumor formation in human HuH6 hepatoblastoma cells. PLoS One.
14:e02144692019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sonoda Y, Yamamoto D, Sakurai S, Hasegawa
M, Aizu-Yokota E, Momoi T and Kasahara T: FTY720, a novel
immunosuppressive agent, induces apoptosis in human glioma cells.
Biochem Biophys Res Commun. 281:282–288. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lepley D, Paik JH, Hla T and Ferrer F: The
G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to
inhibit tumor cell migration. Cancer Res. 65:3788–3795. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stallings-Mann ML, Waldmann J, Zhang Y,
Miller E, Gauthier ML, Visscher DW, Downey GP, Radisky ES, Fields
AP and Radisky DC: Matrix metalloproteinase induction of Rac1b, a
key effector of lung cancer progression. Sci Transl Med.
4:142ra952012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang WH, Lan HY, Huang CH, Tai SK, Tzeng
CH, Kao SY, Wu KJ, Hung MC and Yang MH: RAC1 activation mediates
Twist1-induced cancer cell migration. Nat Cell Biol. 14:366–374.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sato Y, Kurose A, Ogawa A, Ogasawara K,
Traganos F, Darzynkiewicz Z and Sawai T: Diversity of DNA damage
response of astrocytes and glioblastoma cell lines with various p53
status to treatment with etoposide and temozolomide. Cancer Biol
Ther. 8:452–457. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Davis ME: Glioblastoma: Overview of
disease and treatment. Clin J Oncol Nurs. 20(Suppl 5): S2–S8. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sharim J, Tashjian R, Golzy N and
Pouratian N: Glioblastoma following treatment with fingolimod for
relapsing-remitting multiple sclerosis. J Clin Neurosci.
30:166–168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hyland MH and Cohen JA: Fingolimod. Neurol
Clin Pract. 1:61–65. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rothhammer V, Kenison JE, Tjon E, Takenaka
MC, de Lima KA, Borucki DM, Chao CC, Wilz A, Blain M, Healy L, et
al: Sphingosine 1-phosphate receptor modulation suppresses
pathogenic astrocyte activation and chronic progressive CNS
inflammation. Proc Natl Acad Sci USA. 114:2012–2017. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kappos L, Radue EW, O'Connor P, Polman C,
Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M,
Zhang-Auberson L, et al: A Placebo-controlled trial of oral
fingolimod in relapsing multiple sclerosis. N Engl J Med.
362:387–401. 2010. View Article : Google Scholar : PubMed/NCBI
|
